Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3606873 | 0.98 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNACXCR4HTTCNR1 | |
| Trifluoroacetic Acid SCHEMBL465779 | 0.87 | SMN1; SMN2 (0.75) | SMN1; SMN2LMNACXCR4CNR1KCNH2 | |
| SCHEMBL1033875 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNADRD2DRD4DRD3 | |
| SCHEMBL3624985 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2LMNACXCR4RAB9AGABRA5 | |
| SCHEMBL3632268 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNADRD2DRD4DRD3 | |
| SCHEMBL13551047 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2CXCR4HTTCNR1KCNH2 | |
| SCHEMBL20605747 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2CXCR4HTTCNR1KCNH2 | |
| SCHEMBL1419909 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNACXCR4HTTCNR1 | |
| SCHEMBL12654050 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2CXCR4HTTCNR1KCNH2 | |
| SCHEMBL9072421 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | claimed |
| US-12313546-B2 | Sensing devices and chemosensors and compositions relating thereto | ROBERT BOSCH GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| US-20220034808-A1 | SENSING DEVICES AND CHEMOSENSORS AND COMPOSITIONS RELATING THERETO | ROBERT BOSCH GMBH (DE) | 2022-02-03 | — | — | US | disclosed |
| US-9957271-B2 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957271-B2 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| CN-102083438-B | The quinoline of conditioning agent and related analogs as silent message regulatory factor | 西特里斯药业公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
| WO-2008138842-A1 | IMIDAZOPYRAZINES AND TRIAZOLOPYRAZINE FOR THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138842-A1 | IMIDAZOPYRAZINES AND TRIAZOLOPYRAZINE FOR THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1896434-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006076632-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFκB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | TNF, LITAF, CNKSR1 | SMN1; SMN2 1423/4885LMNA 1886/4885CXCR4 1465/4885 |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKB2, NFKB1 | SMN1; SMN2 4730/4885LMNA 4082/4885CXCR4 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.